Overhauling oversight—European drug legislation
- 1 September 2005
- journal article
- Published by Springer Nature in Nature Biotechnology
- Vol. 23 (9) , 1050-1053
- https://doi.org/10.1038/nbt0905-1050
Abstract
At the end of next month, the European Medicines Agency (EMEA) will implement a new legislative framework and several provisions that seek to provide incentives and streamline regulatory oversight of certain monoclonal antibodies and other biologic products.Keywords
This publication has 3 references indexed in Scilit:
- Tysabri raises alarm bells on drug classNature Biotechnology, 2005
- FDA and EMEA pool scientific adviceNature Biotechnology, 2004
- Finland Joins the European UnionPublished by Taylor & Francis ,2004